PDF(Pubmed)
Abstract：
Immunosenescence is the adverse change in the human immune function during aging, leaving older people more prone to an increased risk of infections and morbidity. Acute upper respiratory tract infections (URTIs) are very common among older people, often resulting in continued morbidity and mortality. Therefore, approaches, such as consuming probiotics, that shorten the duration or even reduce the incidence of URTIs in older people are being studied. The aim of this study was to determine the effects of a multi-strain probiotic OMNi-BiOTiC® Active, which contains 11 live probiotic strains, on the incidence, duration, and severity of URTIs in older people. In this randomized double-blinded placebo-controlled study, 95 participants, with an average age of 70.9 years in the probiotic group and 69.6 years in the placebo group, were randomly allocated to two groups: 1010 cfu per day of the multi-strain probiotic intervention OMNi-BiOTiC® Active (49) or placebo (46). The incidence of URTIs in older people after 12 weeks supplementation with OMNi-BiOTiC® showed no statistically significant difference between the two groups (p = 0.5244). However, the duration of the URTI infections was statistically significantly different between the groups (p = 0.011). The participants that consumed the probiotic had an average duration of illness of 3.1 ± 1.6 days, whilst participants that received the placebo had symptoms for an average of 6.0 ± 3.8 days (p = 0.011). Statistically significant differences in lymphocyte counts in both groups after supplementation (p = 0.035 for the probiotic group and p = 0.029 for the placebo group) and between both groups were found (p = 0.009). Statistically significant differences in eosinophil (p = 0.002) and basophil counts (p = 0.001) in the probiotic groups before and after supplementation with probiotics were also found. Supplementation with the multi-strain probiotic OMNi-BiOTiC® Active may benefit older people with URTIs. Larger randomised controlled clinical trials are warranted. Clinical Trial Registration; identifier NCT05879393.
摘要：
免疫衰老是衰老过程中人体免疫功能的不良变化,使老年人更容易感染和发病的风险增加。急性上呼吸道感染（URTIs）在老年人中非常常见，经常导致持续的发病率和死亡率。因此,方法，比如食用益生菌，正在研究缩短持续时间甚至减少老年人URTIs的发生率。本研究的目的是确定多菌株益生菌OMNi-BiOTiC®Active，其中包含11种活的益生菌菌株，关于发病率，持续时间,和严重的URTIs在老年人。在这项随机双盲安慰剂对照研究中，95人益生菌组的平均年龄为70.9岁，安慰剂组的平均年龄为69.6岁，随机分为两组：每天1010cfu的多菌株益生菌干预OMNi-BiOTiC®Active（49）或安慰剂（46）。补充OMNi-BiOTiC®12周后，老年人URTIs的发生率在两组之间没有统计学上的显着差异（p=0.5244）。然而,URTI感染的持续时间在组间有统计学显著差异(p=0.011).服用益生菌的参与者平均患病时间为3.1±1.6天，而接受安慰剂的参与者出现症状的时间平均为6.0±3.8天(p=0.011).发现补充后两组（益生菌组p=0.035，安慰剂组p=0.029）和两组之间的淋巴细胞计数存在统计学上的显着差异（p=0.009）。在补充益生菌前后，益生菌组的嗜酸性粒细胞（p=0.002）和嗜碱性粒细胞计数（p=0.001）也存在统计学上的显着差异。补充多菌株益生菌OMNi-BiOTiC®Active可能会使患有URTI的老年人受益。有必要进行较大的随机对照临床试验。临床试验注册；标识符NCT05879393。
